Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial
PaperCitations, authors & open-access status
Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 115 citations, 2023 year and hybrid oa status.
115
Citations
2023
Year
hybrid
OA Status